PepGen
Market cap $269M 69.3M shares (10-Q, Nov 4, 2026) × $3.88 close Nov 17, 2026
Most recent annual filing: 2026-03-04
- PGN-EDODM1 readout1H 2027PGN-EDODM1 readout, 1H 2027, material
- PGN-EDODM1 interimJan 2027PGN-EDODM1 interim, Jan 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (1 active programs)
Technology platforms
EDO
Enhanced Delivery Oligonucleotide platform leveraging cell-penetrating peptides (CPPs) conjugated to oligonucleotide therapeutics (PPMOs) to optimize tissue penetration, cellular uptake, and nuclear delivery; focus on neuromuscular and neurologic diseases including myotonic dystrophy type 1
Targets: DMPK
Discontinued (1)
- PGN-EDO51 — Duchenne Muscular Dystrophy · voluntary discontinuation of DMD program announced May 28, 2025
Capital (as filed)
- Cash
- $22.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $82.8M Sep 30, 2026
- Operating cash flow
- −$13.2M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $222M cash, runway 1H 2027 and 2H 2027 catalysts per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (5)
- 2026-11-18 UPDATE: PepGen (PEPG) - The Anchor Bought In 🔒 Paid
- 2026-11-13 UPDATE: PepGen (PEPG) - Priced Above the Gap 🔒 Paid
- 2026-11-11 UPDATE: PepGen (PEPG) - The Coin Landed Heads, Then the Dilution Gun Fired 🔒 Paid
- 2026-08-07 UPDATE: PepGen (PEPG) - The DSMB Blinked First 🔒 Paid
- 2026-05-29 PepGen (PEPG) — Scientific Deep Dive for PGN-EDODM1 and the EDO Platform 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (5 calls)
Every verdict Biotech Distilled has published on PepGen, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-29 Watch PepGen (PEPG) — Scientific Deep Dive for PGN-EDODM1 and the EDO Platform Differentiated chemistry and a $12B strategic precedent are real, but the 5 mg/kg MAD miss, FDA partial hold, kidney signal, late competitive position, and loaded $400M shelf make this a wait-and-watch into the 2H 2026 binary event.
- 2026-08-07 Speculative buy speculative UPDATE: PepGen (PEPG) - The DSMB Blinked First DSMB clearance for 10 mg/kg repeat dosing retired the kidney-signal trapdoor, dilution risk is no longer forced, and the binary readout now has a dated November catalyst — warranting a small speculative position.
- 2026-11-11 Buy core UPDATE: PepGen (PEPG) - The Coin Landed Heads, Then the Dilution Gun Fired The 10 mg/kg readout delivered 46.5% ITT-clean splicing correction with durable functional signals and manageable kidney safety, de-risking the core efficacy question and warranting an upgrade to Accumulate into the offering price.
- 2026-11-13 Buy core UPDATE: PepGen (PEPG) - Priced Above the Gap The offering priced above the pre-launch close at $5.00, confirming institutional demand; the story is unchanged but the expected discount never arrived, so accumulation is maintained with preference for pullbacks toward or below the deal price.
- 2026-11-18 Buy core UPDATE: PepGen (PEPG) - The Anchor Bought In RA Capital bought $43.1M at $5.00 and raised its stake to 30.5% while the stock fell 23% below the deal price, confirming anchor conviction and making the pullback the better entry the author had flagged.
- Long call · opened Aug 7, 2026 at $2.85 · +36.1% vs XBI -7.7% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (25)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026SCHEDULE 13D/A13D amendment→ BD updateRA Capital answered the question I told readers to watch: they bought 8,625,000 shares at $5.00 in the November offering — $43.1M of conviction — and now hold 30.5% of PEPG while the stock trades at $3.88, 22% below their average cost.
- Nov 12, 20268-KCurrent report: material agreement, other events · EX-99.1→ BD updateThe $125M offering priced at $5.00 — a slim premium to Tuesday's data-pop close, no warrants, and a clean institutional syndicate. Here's what the terms tell you about where the smart money is sizing this.
- Nov 12, 2026424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- Nov 11, 2026ReleasePepGen Announces Pricing of $125 Million Public Offering
- Nov 10, 2026ReleasePepGen Announces Proposed $125.0 Million Public Offering of Common Stock→ BD updateSummary on the 8-K
- Nov 10, 2026ReleasePepGen Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights→ BD updateSummary on the 8-K
- Nov 10, 2026ReleasePepGen Announces Positive Phase 2 FREEDOM2-DM1 10 mg/kg Results Demonstrating Highest Reported Splicing Correction and Improvements Across Multiple Functional Measures→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1→ BD updateThe binary 10 mg/kg FREEDOM2 readout delivered — 46.5% mean splicing correction on ITT, functional improvements across myotonia, grip and mobility, clean safety, and no outlier exclusions needed. The stock nearly doubled on the news, and PepGen immediately launched a $125M follow-on offering after the close.
- Nov 10, 2026424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Aug 6, 2026ReleasePepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Reviewvia aggregatorBD extracted 1 program update from this document → PEPG pipeline
- Aug 6, 2026ReleasePepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlightsvia aggregator
- Aug 6, 20268-KCurrent report: results of operations, Reg FD disclosure, other events · EX-99.1
- Aug 6, 202610-QQuarterly report
- Jun 22, 20268-KCurrent report: shareholder vote
- May 21, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- May 18, 2026S-3Shelf registration
- May 12, 20268-KCurrent report: results of operations · EX-99.1
- May 12, 202610-QQuarterly report
- Apr 28, 2026DEFA14AProxy soliciting material
- Apr 28, 2026DEF 14AProxy statement
- Mar 30, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Mar 4, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Mar 4, 20268-KCurrent report: results of operations, other events · EX-99.1
- Mar 4, 202610-KAnnual report
9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- May 21, 2026EFFECTRegistration effective
- May 19, 2026CORRESPCORRESP
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 28, 2026ARSAnnual report to shareholders
- Apr 17, 2026UPLOADUPLOAD
- Apr 15, 2026DRSDRS
- Mar 11, 2026SCHEDULE 13GPassive >5% holder (13G)
- Mar 4, 2026S-8Employee plan registration